Biotron Limited · ASX:BIT

Biotron — Singapore Biotech Invest 2016 / Asia Biotech Invest 2016

11 slides from Biotron's conference presentation, May 2016

  1. Slide 1: Biotron Limited (ASX:BIT) Singapore Biotech Invest 2016

    BIOTRON LIMITED (ASX:BIT) Singapore Biotech Invest 2016 Asia Biotech Invest 2016

  2. Slide 2: Forward Looking Statements

    Forward Looking Statements This presenta,on may contain forward-­‐looking statements with respect to the financial condi,on, results and business achievements/performance of Biotron Limited (ACN 086 399 144) and certain of the plans and objec,ves of its management. These statements are statements tha

  3. Slide 3: Biotron Limited Overview

    Biotron Limited Overview • Clinical stage drug development company • Drug development plaWorm for new class of an,viral drugs • Phase 2 clinical programs for Hepa,,s C virus (HCV) and HIV-­‐1 • Earlier stage programs include Dengue, Influenza and others • Headquartered in Sydney, Australia INDICATION

  4. Slide 4: Biotron's Core Technology

    Biotron’s Core Technology OTHER “HITS” IN LIBRARY include: Designed library of Compounds screened in compounds to target proprietary assay set up for viroporins: each virus target e.g. HIV-­‐1 -­‐ Influenza A and B Vpu; HCV p7; Influenza M2; -­‐ Coronaviruses IniZally >250 compounds designed and synth

  5. Slide 5: BIT225 – First of a New Class of HCV DAA Drugs

    BIT225 – First of a New Class of HCV DAA Drugs ü Novel, oral, small molecule compound POLYMERASE/PROTEASE INHIBITORS e.g. Sofosbuvir/Simeprevir ü Only one of its class (p7 inhibitor) in clinical trials ü Inhibits viral assembly and infec,vity BIT225 -­‐ ASSEMBLY/ BUDDING INHIBITOR ü Pan-­‐genoty

  6. Slide 6: Positioning BIT225 within HCV Landscape

    PosiZoning BIT225 within HCV Landscape • HCV market predicted to earn US$36 billion in 2018 • 180 million infected worldwide (3% world popula,on) • Recent new HCV drug combina,ons are good, but not op,mal • Lengthy treatment – 12 weeks or more • Not pan-­‐genotypic – BIT225 is pan-­‐genotypic in vit

  7. Slide 7: HIV-1: Towards a Cure

    HIV-­‐1: Towards a Cure • HIV-­‐1 remains hidden in reservoirs, leading to chronic, life-­‐ long infec,on – Invisible to body’s immune defenses – Not sensi,ve to an,-­‐HIV-­‐1 drugs • Pa,ents need to stay on an,retroviral drugs to keep virus levels under control • Long-­‐term health implica,ons • Ne

  8. Slide 8: Unlocking Value for Other Virus Targets

    Unlocking Value for Other Virus Targets • Renewed industry interest in targe,ng viral diseases including • Respiratory syncy,al virus (RSV) • Hepa,,s B virus • Tropical diseases including Dengue • Influenza (in par,cular drug resistant strains) • Ebola and MERS-­‐CoV outbreaks have caused public heal

  9. Slide 9: Dengue Virus Program

    Dengue Virus Program • 2.5 billion people (40% world popula,on) live in areas at risk of Dengue • ~100 million people infected yearly • A leading cause of illness and death in tropics and subtropics • Transmission is by mosquito; most preven,on programs target the vector • No approved Dengue-­‐speci

  10. Slide 10: Financial Information

    Financial InformaZon Key Financial Metrics Ticker Code 6 Month Share Price Performance ASX: BIT Share Price (29/04/16) A $0.063 Ticker Code ASX: BIT Market cap A $20 million Share Price (15 Sept 2014) A $0.115 12 Month Trading Range A $0.041 – 0.150 Market cap A $26.3 million Shares Outstanding 313

  11. Slide 11: www.biotron.com.au

    Dr Michelle Miller Managing Director +61 412 313329 mmiller@biotron.com.au www.biotron.com.au

Biotron — Singapore Biotech Invest 2016 / Asia Biotech Invest 2016 on 6ix